ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,022,682 | $521,780 | $340,825 | $192,289 |
| - Cash | $50,817 | $70,971 | $210,518 | $60,063 |
| + Debt | $42 | $274 | $481 | $9,033 |
| Enterprise Value | $971,907 | $451,083 | $130,788 | $141,259 |
| Revenue | $89,149 | $30 | $1,316 | $5,506 |
| % Growth | 297,063.3% | -97.7% | -76.1% | – |
| Gross Profit | $68,592 | $30 | $1,316 | $5,293 |
| % Margin | 76.9% | 100% | 100% | 96.1% |
| EBITDA | -$3,004 | -$67,447 | -$35,197 | -$19,241 |
| % Margin | -3.4% | -224,823.3% | -2,674.5% | -349.5% |
| Net Income | $7,998 | -$54,365 | -$34,682 | -$20,243 |
| % Margin | 9% | -181,216.7% | -2,635.4% | -367.7% |
| EPS Diluted | 0.078 | -0.57 | -0.87 | -0.7 |
| % Growth | 113.7% | 34.5% | -24.3% | – |
| Operating Cash Flow | $13,548 | -$59,266 | -$40,078 | -$17,561 |
| Capital Expenditures | -$563 | -$175 | -$199 | -$55 |
| Free Cash Flow | $12,985 | -$59,441 | -$40,277 | -$17,616 |